Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

[Castration-resistant prostate cancer: where are we going?].

Alcaraz A, Medina R, Maroto P, Climent MÁ, Castellano D, Carles J.

Actas Urol Esp. 2012 Jun;36(6):367-74. doi: 10.1016/j.acuro.2011.10.010. Epub 2011 Dec 19. Review. Spanish.

PMID:
22188754
2.

Castration-resistant metastatic prostate cancer: current status and treatment possibilities.

Carles J, Castellano D, Climent MÁ, Maroto P, Medina R, Alcaraz A.

Clin Transl Oncol. 2012 Mar;14(3):169-76. doi: 10.1007/s12094-012-0780-8. Review.

PMID:
22374419
3.

Castration-resistant prostate cancer: systemic therapy in 2012.

Maluf FC, Smaletz O, Herchenhorn D.

Clinics (Sao Paulo). 2012;67(4):389-94. Review.

4.
5.

Novel strategies in the treatment of castration-resistant prostate cancer (Review).

Marech I, Vacca A, Ranieri G, Gnoni A, Dammacco F.

Int J Oncol. 2012 May;40(5):1313-20. doi: 10.3892/ijo.2012.1364. Epub 2012 Feb 9. Review.

PMID:
22322981
6.

[EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].

Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, Heidenreich A.

Actas Urol Esp. 2011 Nov-Dec;35(10):565-79. doi: 10.1016/j.acuro.2011.03.011. Epub 2011 Jul 14. Spanish.

PMID:
21757258
7.

Emerging and second line therapies for the management of metastatic castration-resistant prostate cancer: the Australian perspective.

Parente P, Parnis F, Gurney H.

Asia Pac J Clin Oncol. 2012 Mar;8(1):31-42. doi: 10.1111/j.1743-7563.2011.01506.x. Review.

PMID:
22369442
8.

[Role of chemotherapy in castration-resistant prostate cancer: are there new approaches?].

De Santis M, Bachner M.

Urologe A. 2012 Jan;51(1):39-43. doi: 10.1007/s00120-011-2739-8. German.

PMID:
22258375
9.

[Strategy in advanced castration-resistant prostate cancer].

Gross-Goupil M, Roca S, Pasticier G, Ravaud A.

Bull Cancer. 2012 Jul;99 Suppl 1:S37-45. doi: 10.1684/bdc.2012.1562. Review. French.

PMID:
22522582
10.

Chemotherapy-based treatment for castration-resistant prostate cancer.

Seruga B, Tannock IF.

J Clin Oncol. 2011 Sep 20;29(27):3686-94. doi: 10.1200/JCO.2010.34.3996. Epub 2011 Aug 15. Review. Erratum in: J Clin Oncol. 2011 Dec 20;29(36):4847. Dosage error in article text.

PMID:
21844499
11.

Current second-line treatment options for patients with castration resistant prostate cancer (CRPC) resistant to docetaxel.

Arsov C, Winter C, Rabenalt R, Albers P.

Urol Oncol. 2012 Nov-Dec;30(6):762-71. doi: 10.1016/j.urolonc.2010.02.001. Epub 2010 Sep 29. Review.

PMID:
20884252
12.

New agents for the management of castration-resistant prostate cancer.

Cersosimo RJ.

Ann Pharmacother. 2012 Nov;46(11):1518-28. doi: 10.1345/aph.1R169. Epub 2012 Nov 7. Review.

PMID:
23136351
13.

[How should hormone therapy for castration-resistant prostate cancer be continued?].

Spahn M, Krebs M.

Urologe A. 2012 Jan;51(1):15-9. doi: 10.1007/s00120-011-2738-9. German.

PMID:
22258371
14.

Treatment options in hormone-refractory prostate cancer: current and future approaches.

Harris KA, Reese DM.

Drugs. 2001;61(15):2177-92. Review.

PMID:
11772129
15.

Second-line chemotherapy in metastatic docetaxel-resistant prostate cancer: a review.

Colloca G, Venturino A, Checcaglini F.

Med Oncol. 2012 Jun;29(2):776-85. doi: 10.1007/s12032-011-9855-6. Epub 2011 Feb 20. Review.

PMID:
21336988
16.

Overcoming castration resistance in prostate cancer.

Tsao CK, Small AC, Galsky MD, Oh WK.

Curr Opin Urol. 2012 May;22(3):167-74. doi: 10.1097/MOU.0b013e3283523b8b. Review.

PMID:
22472508
17.

[Cabazitaxel after docetaxel: a new option in metastatic castration-resistant prostate cancer].

Lheureux S, Joly F.

Bull Cancer. 2012 Sep;99(9):875-80. doi: 10.1684/bdc.2012.1617. French.

PMID:
22877855
18.

Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: a cost-effectiveness analysis.

Zhong L, Pon V, Srinivas S, Nguyen N, Frear M, Kwon S, Gong C, Malmstrom R, Wilson L.

PLoS One. 2013 May 22;8(5):e64275. doi: 10.1371/journal.pone.0064275. Print 2013.

19.

[Third generation anti-androgen therapy of advanced prostate cancer].

Ohlmann CH, Kamradt J, Stöckle M.

Urologe A. 2012 Apr;51(4):522-6. doi: 10.1007/s00120-011-2760-y. Review. German.

PMID:
22113551
20.

Recent advances in second-line treatment of castration-resistant prostate cancer.

Ong M, Winquist E.

Curr Opin Support Palliat Care. 2011 Sep;5(3):199-205. doi: 10.1097/SPC.0b013e32834903aa. Review.

PMID:
21734586
Items per page

Supplemental Content

Write to the Help Desk